Section S1 shows descriptive statistics of two datasets that were tested in the paper. Section S2 presents sensitivity analysis of parameter K for constructing the underlying graph of our CRF model. Section S3 describes the comparison results on constructing the underlying graph of our CRF model using different criteria. Section S4 shows the results of the 5-fold cross-validation test that was performed in the paper. Section S5 provides the descriptions of different approaches tested in Section 3.3 of the paper.
Section S1 shows descriptive statistics of two datasets that were tested in the paper. Section S2 presents sensitivity analysis of parameter K for constructing the underlying graph of our CRF model. Section S3 describes the comparison results on constructing the underlying graph of our CRF model using different criteria. Section S4 shows the results of the 5-fold cross-validation test that was performed in the paper. Section S5 provides the descriptions of different approaches tested in Section 3.3 of the paper. Table S1 shows descriptive statistics of two datasets that were tested in the paper.
S1 Descriptive Statistics of Two Datasets

Statistics
First Dataset Second Dataset
Number of drugs 875 357
Number of proteins 249 220
Number of interactions 2596 1174
Average degree for a drug 3.0 3.3
Average degree for a protein 10.4 5.3 Table S1 : Descriptive statistics of two datasets tested in the paper.
S2 Sensitivity Analysis of Parameter K for Constructing the Underlying Graph
To choose a proper value of parameter K for constructing the underlying graph, we tested our algorithm on the first dataset using different values of K. Our test was based on target-based CRFs with sequence similarity using 10-fold cross-validation. As shown in 
S3 Comparison Results on Constructing the Underlying Graph Using Different Criteria
We compared the performance of our algorithm using different approaches for constructing the underlying graph of our CRF model. We first connected two nodes if their similarity score was larger than a chosen threshold. Then we checked if degree of each node was at least K. For any node whose degree was less than K, we added more edges according to the similarity score until its degree was up to K. The case when K = 0 in fact corresponded to the threshold-based approach, as described in the paper (Sec 3.1). Our test was performed on target-based CRFs with sequence similarity using 10-fold cross-validation. Table S3 shows the AUPR results in this comparison test. Table S3 : The AUPR results on constructing the underlying graph of our CRF model using different criteria.
The test was performed on target-based CRFs with sequence similarity using 10-fold cross-validation. Table S4 shows the results of the 5-fold cross-validation test on the first dataset using different approaches.
S4 5-fold Cross-validation on the First Dataset
Compared to the results of the 10-fold cross-validation test described in the paper, only a slight decrease in AUC and AUPR was observed. Table S4 : The 5-fold cross-validation results on the first dataset using different approaches. The best result is shown in bold.
Approach Evaluation Criterion AUC AUPR
S5 Descriptions of Different Approaches Tested in Section 3.3 in the Paper
• AERS-freq-based pharmacogenomic approach (AERS-freq): The test was performed on genomic and AERS-freq-based pharmacological data.
• AERS-bit-based pharmacogenomic approach (AERS-bit): The test was performed on genomic and AERS-bit-based pharmacological data.
• SIDER-based pharmacogenomic approach (SIDER): The test was performed on genomic and SIDERbased pharmacological data.
• JAPIC-based pharmacogenomic approach (JAPIC): The test was performed on genomic and JAPICbased pharmacological data.
• Chemogenomic approach (CHEM): The test was performed on genomic and chemical data.
• Integrated pharmacogenomic approach (INTEG-P): The test was performed on genomic, AERS-freqbased, SIDER-based and JAPIC-based pharmacological data.
• Integrated pharmaco-chemogenomic approach (INTEG-PC): The test was performed on genomic, chemical, AERS-freq-based, SIDER-based and JAPIC-based pharmacological data.
